Bevacizumab for the Treatment of Corneal Neovascularization

Sponsor
Chang Gung Memorial Hospital
Study ID
NCT00992849
Phase
PHASE2
Status
Unknown

Conditions

  • Corneal Neovascularization

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc

Study Details

The purpose of the current study is to assess the efficacy and safety of the inhibitory effect of bevacizumab (Avastin) with different routes including topical and subconjunctival application on corneal neovascularization in the human eyes.

Key Dates

First listed
Oct 9, 2009
Start date
May 31, 2009
Status verified
Oct 2009
Primary completion
Apr 30, 2010
Completion
Apr 30, 2012

Study Design

Enrollment
10 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab
    Arm type to experimental based on single group assignment. Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF).VEGF is a chemical signal that stimulates the growth of new blood vessels.

Primary Outcome Measure

Regression of corneal neovascularization [ Time Frame: 6 months ]

Related Studies